Detail of "274-83-9"

Reference

1,2,4-Triazolo[4,3-b]pyridazine derivatives and their use in treatment of neurological disorders

1,2,4-Triazolo[4,3-b]pyridazine derivatives and their use in treatment of neurological disorders. Sargent, Bruce Jeremy; Fernandez, Fernandez Maria Isabel; Villanueva, Inurrategui Maria Asabel (Knoll Aktiengesellschaft, Germany). PCT Int. Appl. WO 9632393 A1 17 Oct 1996, 44 pp. DESIGNATED STATES: W: CN, JP, US; RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: C07D487-04. ICS: A61K031-50. ICI: C07D487-04, C07D249-00, C07D237-00. APPLICATION: WO 1996-EP1387 29 Mar 1996. PRIORITY: GB 1995-7348 8 Apr 1995. DOCUMENT TYPE: Patent CA Section: 28 (Heterocyclic Compounds (More Than One Hetero Atom)) Section cross-reference(s): 1 Title compds. I and their pharmaceutically acceptable salts are disclosed [wherein R1 = H, cyano, (di)(alkyl)amino, (un)substituted C1-6 alkyl, alkoxy, or alkanoyl; R2, R3 = H, (un)substituted C1-6alkyl, alkoxy, alkanoyl, alkylthio, alkylsulphinyl, or alkylsulfonyl; R4, R5 = H, C1-6 alkyl; or CR4R5 = (un)substituted C3-6 cycloalkylidene; R6, R7, R8 = H, halo, OH, SH, cyano, (un)substituted C1-6alkyl, alkanoyl, alkoxy, alkoxycarbonyl, CO2H, alkanoyloxy, alkylthio, alkylsulphinyl, alkyllsulfonyl, alkylsulfonylamino, sulfamoyl, carbamoyl, alkylcarbamoyl, alkanoylamino].Chemical with cas number 30343-25-0 also plays role. I have utility in the treatment, prophylaxis, and/or inhibition of seizures, neurol. disorders such as epilepsy, and/or conditions in which there is neurol. damage, such as stroke, brain trauma, cerebral ischemia, head injuries, and hemorrhage. For example, cyclization of 4-(4-chlorophenoxy)-1-(dimethylamino)-1-penten-3-one (prepn. given) with 4-amino-1,2,4-triazole in refluxing glacial AcOH gave title compd. II. This compd. had an oral ED50 of 43.7 mg/kg for inhibition of seizures in the maximal electroshock test in mice. .

The crystal structures of s-triazolo[4,3-b]pyridazine,s-triazolo[1,5-b]pyridazine and tetrazolo[1,5-b]pyridazine

The crystal structures of s-triazolo[4,3-b]pyridazine,s-triazolo[1,5-b]pyridazine and tetrazolo[1,5-b]pyridazine. Golic, L.; Leban, I.; Stanovnik, B.; Tisler, M. (Chem. Dep., Univ. Ljubljana, Ljubljana, Yugoslavia). Acta Crystallogr., Sect. B, B34(4), 1136-40 (English) 1978. CODEN: ACBCAR. ISSN: 0567-7408. DOCUMENT TYPE: Journal CA Section: 75 (Crystallization and Crystal Structure) Section cross-reference(s): 28 Triazolo[4,3-g]pyridazine, C5H4N4, (I) is monoclinic, space group P21/c, with a 7.378(2), b 10.845(2), c ?, and b 118.78(2)°; d.(obsd.) = 1.52(5) and d.(calcd.) = 1.510 for Z = 4. Triazolo[1,5-b]pyridazine, C5H4N4, is monoclinic, space group P21, with a 3.737(2), b 6.647(2), c 10.756(2) ?, and b 93.30(2)°; d.(obsd.) = 1.52(5), and d.(calcd.) = 1.496 for Z = 2. Tetrazolo[1,5-b]pyridazine, C4H3N5, (III) is monoclinic, space group P21/n, with a 6.148(2), b 8.026(2), c 10.509(2) ?, and b 94.84(2)°; d.(obsd.) = 1.57(5) and d.(calcd.) = 1.557 for Z = 4. The structures were solved by direct methods and refined by full-matrix least-squares to final R of 0,055, 0.085, 0.054 for I, II, and III, resp. The mols. are essentially planar.Some commonly used reagents like 274-83-9 is used in this experiment. Most of the bond lengths and angles are within normal ranges for arom. heterocyclic systems, apart from the N(5)-C(6) and C(7)-C(8) bonds in I (1.296(3) and 1.354(3) ? and III (1.298(3) and 1.353(3) ?) which demonstrate considerable double-bond character. .